Data from Frequent <i>Met</i> Oncogene Amplification in a <i>Brca1/Trp53</i> Mouse Model of Mammary Tumorigenesis

Gromoslaw A. Smolen,Beth Muir,Gayatry Mohapatra,Anne Barmettler,Woo J. Kim,Miguel N. Rivera,Sara M. Haserlat,Ross A. Okimoto,Eunice Kwak,Sonika Dahiya,Judy E. Garber,Daphne W. Bell,Dennis C. Sgroi,Lynda Chin,Chu-Xia Deng,Daniel A. Haber
DOI: https://doi.org/10.1158/0008-5472.c.6495387.v1
2023-01-01
Abstract:<div>Abstract<p>In a screen for gene copy number alterations in mouse mammary tumors initiated by loss of the <i>Brca1</i> and <i>Trp53</i> genes, we observed that the majority (11 of 15; 73%) had high-level amplification of wild-type <i>Met</i>, encoding a growth factor receptor implicated in tumor progression. <i>Met</i> amplification was localized to unstable double minute chromosomes and was uniquely found in mouse breast tumors driven by loss of <i>Brca1</i> and <i>Trp53</i>. Whereas analogous <i>MET</i> amplification was not found in human breast cancers, the identification of a dominant somatic genetic lesion in the <i>Brca1/Trp53</i> mouse model suggests that recurrent secondary hits may also exist in <i>BRCA1</i>-initiated human breast cancer. (Cancer Res 2006; 66(7): 3452-5)</p></div>
What problem does this paper attempt to address?